News Archive

Symphogen announces the appointment of Jeffrey H. Buchalter and Christoffer Søderberg as Non-Executive Directors

COPENHAGEN, Denmark (11 May, 2016)
Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today the appointment to the company's Board of Directors two new Non-Executive Directors: Mr. Jeffrey H. Buchalter and Mr. Christoffer Søderberg, effective 10 May 2016.

Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today the appointment to the company's Board of Directors two new Non-Executive Directors: Mr. Jeffrey H. Buchalter and Mr. Christoffer Søderberg, effective 10 May 2016.

 

Jeffrey H. Buchalter has over thirty years' experience in the bio/pharmaceutical industry. His experience combines strong corporate leadership allied to an extensive background in medical/clinical research with multinational organizations. He brings extensive commercial and drug development experience in oncology and other therapeutic areas. 

 

Jeffrey has been recognized for his work, receiving the Joseph F. Buckley Memorial Award from the American Cancer Society for commitment to cancer control and involvement in the oncology pharmaceutical field.  He has also been a Collaborating Partner in the President's National Dialogue on Cancer and acted as Chairman of the Board of Directors to the National Childhood Cancer Foundation in the United States. 

 

Jeffrey received a Bachelor of Science Degree in Finance from Seton Hall University and a Master of Business Administration in Marketing from Temple University.

 

Christoffer Søderberg, has been a Director, Large Investments at Novo A/S since February 2016 leading investment processes and taking part in managing and developing the portfolio of investments.  

 

Prior to joining Novo A/S, Christoffer was a Senior Principal at the Boston Consulting Group (BCG) leading the Copenhagen Private Equity and Principal Investors practice area. Prior to joining BCG, Christoffer worked at Falck A/S as Global Head of Group Strategy and M&A, and most recently as CFO Falck Assistance. Prior to joining Falck, Christoffer worked as a Director at Carnegie Investment Banking focusing on buy-and sell-side M&A.

 

Christoffer holds a BSc in International Business and an MSc in Finance and Accounting from the Copenhagen Business School.

 

Welcoming the appointment, Göran Ando MD, Chairman of the Board, commented: "I am delighted to welcome Jeff and Christoffer to Symphogen's board of directors. They are both highly respected and experienced in their fields and they will be invaluable to furthering the success of Symphogen". 

 

Jeff Buchalter added: "I am very excited to take part in the development of Symphogen which operates in a very important medical area with significant unmet medical needs and with a business concept aiming at improving therapies for cancer patients".

 

Christoffer Søderberg added: "I am delighted to have the privilege to serve on the Symphogen board. The opportunity to work with my fellow directors and the executive management team to guide Symphogen into its next chapter is exciting".

 

About Symphogen A/S

Symphogen is a private biopharmaceutical company leading the field of recombinant antibody mixtures for therapeutic use in oncology. The European-based company is developing next-generation antibody therapeutics for the treatment of cancer. Symphogen is dedicated to bringing truly innovative oncology products to the market, creating optimally selected antibody mixtures that address multiple oncology targets in a single drug product.  The company has collaborations for the development of antibody therapeutics in the infectious disease area with Genentech and in immuno-oncology with Baxalta Incorporated. Symphogen employs more than 90 people, has offices in Denmark and New Jersey, US and its investors include Essex Woodlands Health Ventures, Novo A/S, PKA, Sunstone Capital, Gilde Healthcare Partners, Danica Pension, Takeda Ventures, Inc., and Genentech.  For more information, please see www.symphogen.com 

 

For additional information, please contact:

Kirsten Drejer

Chief Executive Officer

Phone:  + 45 22 10 99 59

E-mail:  kd@symphogen.com

 

Martin Olin

Chief Financial Officer

Phone: + 45 40 21 85 32

E-mail: mol@symphogen.com

mAb Mixtures and Cancer
Symphogen Reception
Dina and the CEO

Media Inquiries
Heidi K. Roennest
Executive Office Manager
+45 4526 5050
hkr@symphogen.com